Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Net Margin (2021 - 2025)

Oncology Institute's Net Margin history spans 5 years, with the latest figure at 4.53% for Q4 2025.

  • For Q4 2025, Net Margin rose 627.0% year-over-year to 4.53%; the TTM value through Dec 2025 reached 10.7%, up 370.0%, while the annual FY2025 figure was 10.01%, 347.0% up from the prior year.
  • Net Margin reached 4.53% in Q4 2025 per TOI's latest filing, up from 10.08% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 34.96% in Q1 2022 to a low of 39.37% in Q1 2023.
  • Average Net Margin over 5 years is 10.98%, with a median of 12.57% recorded in 2021.
  • Peak YoY movement for Net Margin: soared 2323bps in 2022, then tumbled -7433bps in 2023.
  • A 5-year view of Net Margin shows it stood at 18.99% in 2021, then rose by 19bps to 15.41% in 2022, then tumbled by -42bps to 21.86% in 2023, then soared by 51bps to 10.8% in 2024, then skyrocketed by 58bps to 4.53% in 2025.
  • Per Business Quant, the three most recent readings for TOI's Net Margin are 4.53% (Q4 2025), 10.08% (Q3 2025), and 11.68% (Q2 2025).